Contents

Search

olsalazine (Dipentum)

Tradename: Dipentum. Indications: 1) mild to moderate ulcerative colitis (see mesalamine) 2) 2nd line agent for patients who cannot tolerate sulfasalazine 3) Crohn's disease [4] Dosage: 1) 500-1000 mg PO BID-TID for 3-6 weeks 2) take with food 3) maintenance 500 mg PO BID Tabs: 250 mg. Adverse effects: 1) common (> 10%) - diarrhea, cramps, abdominal pain 2) less common (1-10%) - headache, fatigue, depression, nausea, dyspepsia, bloating, anorexia, rash, itching, arthralgia 3) uncommon (< 1%) - blood dyscrasias, bloody diarrhea, fever, hepatitis 4) other [2] - flatulence - dizziness Mechanism of action: 1) bioconverted in the colon to 2 molecules of mesalamine 2) see mesalamine

Interactions

drug interactions drug adverse effects of NSAIDs monitor with non steroidal anti-inflammatory agents (NSIADs)

Related

mesalamine (Asacol, Rowasa, Pentasa, Pentasacaps, Lialda, Apriso, Canasa, Delzicol)

General

5-aminosalicylate (5-ASA)

Properties

INHIBITS: cyclooxygenase MISC-INFO: elimination route LIVER pregnancy-category C safety in lactation -

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 - not on National VA formulary
  3. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  4. Deprecated Reference